Selective inhibition of platelets by the GPIIb/IIIa receptor antagonist Tirofiban reduces leukocyte-endothelial cell interaction in murine antigen-induced arthritis
Inflammation is associated with the invasion of leukocytes into affected tissues and with the up-regulation of platelet activation and adhesion. Assuming that leukocyte accumulation is linked to platelet aggregation, the aim of our study was to examine the effects of selective platelet inhibition by...
Saved in:
Published in | Inflammation research Vol. 56; no. 10; pp. 414 - 420 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Springer Nature B.V
01.10.2007
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Inflammation is associated with the invasion of leukocytes into affected tissues and with the up-regulation of platelet activation and adhesion. Assuming that leukocyte accumulation is linked to platelet aggregation, the aim of our study was to examine the effects of selective platelet inhibition by the glycoprotein (GP) IIb/IIIa receptor antagonist Tirofiban on the leukocyte-endothelial cell interaction.
We used the model of antigen-induced arthritis (AiA) to induce inflammatory changes in the synovial microcirculation. Ex vivo labelled platelets and in vivo fluorescence-labelled leukocytes were visualized by intravital microscopy (IVM). C57/Bl6 mice were allocated to four groups; two control groups with saline or Tirofiban and two groups with AiA that also received either saline or Tirofiban (0.5 microg/g BW) intravenously.
There was no significant change in platelet- or leukocyte- endothelial cell interaction in the endothelium in healthy control animals. In contrast, after selective inhibition of platelets, the platelet- and leukocyte-endothelial cell interaction was significantly reduced in arthritic mice and reached the level of the healthy control groups.
Selective platelet inhibition by Tirofiban resulted in reduced leukocyte-endothelial cell interactions in AiA. Consequently, platelets contribute to leukocyte adhesion in AiA via GPIIb/IIIa and therefore platelet inhibition could become an additional therapy option in chronic arthritic disease. |
---|---|
AbstractList | Inflammation is associated with the invasion of leukocytes into affected tissues and with the up-regulation of platelet activation and adhesion. Assuming that leukocyte accumulation is linked to platelet aggregation, the aim of our study was to examine the effects of selective platelet inhibition by the glycoprotein (GP) IIb/IIIa receptor antagonist Tirofiban on the leukocyte-endothelial cell interaction. We used the model of antigen-induced arthritis (AiA) to induce inflammatory changes in the synovial microcirculation. Ex vivo labelled platelets and in vivo fluorescence-labelled leukocytes were visualized by intravital microscopy (IVM). C57/Bl6 mice were allocated to four groups; two control groups with saline or Tirofiban and two groups with AiA that also received either saline or Tirofiban (0.5 μg/g BW) intravenously. There was no significant change in platelet- or leukocyte- endothelial cell interaction in the endothelium in healthy control animals. In contrast, after selective inhibition of platelets, the platelet- and leukocyte-endothelial cell interaction was significantly reduced in arthritic mice and reached the level of the healthy control groups. Selective platelet inhibition by Tirofiban resulted in reduced leukocyte-endothelial cell interactions in AiA. Consequently, platelets contribute to leukocyte adhesion in AiA via GPIIb/IIIa and therefore platelet inhibition could become an additional therapy option in chronic arthritic disease. [PUBLICATION ABSTRACT] Objective: Inflammation is associated with the invasion of leukocytes into affected tissues and with the up-regulation of platelet activation and adhesion. Assuming that leukocyte accumulation is linked to platelet aggregation, the aim of our study was to examine the effects of selective platelet inhibition by the glycoprotein (GP) IIb/IIIa receptor antagonist Tirofiban on the leukocyte-endothelial cell interaction. Material and methods: We used the model of antigen-induced arthritis (AiA) to induce inflammatory changes in the synovial microcirculation. Ex vivo labelled platelets and in vivo fluorescence-labelled leukocytes were visualized by intravital microscopy (IVM). C57/B16 mice were allocated to four groups; two control groups with saline or Tirofiban and two groups with AiA that also received either saline or Tirofiban (0.5 mu g/g BW) intravenously. Results: There was no significant change in platelet- or leukocyte-endothelial cell interaction in the endothelium in healthy control animals. In contrast, after selective inhibition of platelets, the platelet- and leukocyte-endothelial cell interaction was significantly reduced in arthritic mice and reached the level of the healthy control groups. Conclusion: Selective platelet inhibition by Tirofiban resulted in reduced leukocyte-endothelial cell interactions in AiA. Consequently, platelets contribute to leukocyte adhesion in AiA via GPIIb/IIIa and therefore platelet inhibition could become an additional therapy option in chronic arthritic disease. OBJECTIVEInflammation is associated with the invasion of leukocytes into affected tissues and with the up-regulation of platelet activation and adhesion. Assuming that leukocyte accumulation is linked to platelet aggregation, the aim of our study was to examine the effects of selective platelet inhibition by the glycoprotein (GP) IIb/IIIa receptor antagonist Tirofiban on the leukocyte-endothelial cell interaction.MATERIAL AND METHODSWe used the model of antigen-induced arthritis (AiA) to induce inflammatory changes in the synovial microcirculation. Ex vivo labelled platelets and in vivo fluorescence-labelled leukocytes were visualized by intravital microscopy (IVM). C57/Bl6 mice were allocated to four groups; two control groups with saline or Tirofiban and two groups with AiA that also received either saline or Tirofiban (0.5 microg/g BW) intravenously.RESULTSThere was no significant change in platelet- or leukocyte- endothelial cell interaction in the endothelium in healthy control animals. In contrast, after selective inhibition of platelets, the platelet- and leukocyte-endothelial cell interaction was significantly reduced in arthritic mice and reached the level of the healthy control groups.CONCLUSIONSelective platelet inhibition by Tirofiban resulted in reduced leukocyte-endothelial cell interactions in AiA. Consequently, platelets contribute to leukocyte adhesion in AiA via GPIIb/IIIa and therefore platelet inhibition could become an additional therapy option in chronic arthritic disease. Inflammation is associated with the invasion of leukocytes into affected tissues and with the up-regulation of platelet activation and adhesion. Assuming that leukocyte accumulation is linked to platelet aggregation, the aim of our study was to examine the effects of selective platelet inhibition by the glycoprotein (GP) IIb/IIIa receptor antagonist Tirofiban on the leukocyte-endothelial cell interaction. We used the model of antigen-induced arthritis (AiA) to induce inflammatory changes in the synovial microcirculation. Ex vivo labelled platelets and in vivo fluorescence-labelled leukocytes were visualized by intravital microscopy (IVM). C57/Bl6 mice were allocated to four groups; two control groups with saline or Tirofiban and two groups with AiA that also received either saline or Tirofiban (0.5 microg/g BW) intravenously. There was no significant change in platelet- or leukocyte- endothelial cell interaction in the endothelium in healthy control animals. In contrast, after selective inhibition of platelets, the platelet- and leukocyte-endothelial cell interaction was significantly reduced in arthritic mice and reached the level of the healthy control groups. Selective platelet inhibition by Tirofiban resulted in reduced leukocyte-endothelial cell interactions in AiA. Consequently, platelets contribute to leukocyte adhesion in AiA via GPIIb/IIIa and therefore platelet inhibition could become an additional therapy option in chronic arthritic disease. |
Author | Gottschalk, O Schmitt-Sody, M Goebl, M Zysk, S Metz, P Birkenmaier, C von Schulze Pellengahr, C Veihelmann, A Jansson, V |
Author_xml | – sequence: 1 givenname: M surname: Schmitt-Sody fullname: Schmitt-Sody, M email: marcus.schmitt-sody@med.uni-muenchen.de organization: Department of Orthopaedics, Klinikum Grosshadern, Ludwig-Maximilians-University, Marchioninistr. 15, 81377, Munich, Germany. marcus.schmitt-sody@med.uni-muenchen.de – sequence: 2 givenname: P surname: Metz fullname: Metz, P – sequence: 3 givenname: O surname: Gottschalk fullname: Gottschalk, O – sequence: 4 givenname: S surname: Zysk fullname: Zysk, S – sequence: 5 givenname: C surname: Birkenmaier fullname: Birkenmaier, C – sequence: 6 givenname: M surname: Goebl fullname: Goebl, M – sequence: 7 givenname: C surname: von Schulze Pellengahr fullname: von Schulze Pellengahr, C – sequence: 8 givenname: A surname: Veihelmann fullname: Veihelmann, A – sequence: 9 givenname: V surname: Jansson fullname: Jansson, V |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/18026698$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkc2KFTEQhYOMOD_6AG4kuJhdnErSP-mlDM7YMKAwM-CuSdLVczP2Ta5JWrjv44Oa9l4Q3LiqA_XVqSrOOTnxwSMhbzl84ADtVQIAzlmRrAVRMfmCnPFKAOtAfTspGoRkUkk4JecpPRdaCSVekVOuQDRNp87Ir3uc0Wb3E6nzG2dcdsHTMNHdrHNp5UTNnuYN0tuvfW-u-r7XNKLFXQ6Rap_1U_AuZfrgYpic0b50x8ViojMu34PdZ2Tox1AsZqdnanGey6qMUds_u5yn2yU6j6ube0LPnF8NRqpj3sRyUHpNXk56TvjmWC_I482nh-vP7O7LbX_98Y5ZWbeZTdI0OFXSWG4qg7VubW25rlqlRw2T1FibSXRSQmVayccROilsN6qmlRZtJy_I5cF3F8OPBVMeti6tB2uPYUlDo2opuFD_BQXUIDrRFvD9P-BzWKIvTwyCN0KqTkCB-AGyMaQUcRp20W113A8chjXo4RD0sMo16EGWmXdH48Vscfw7cUxW_gZQQKlM |
CitedBy_id | crossref_primary_10_1186_s13578_022_00746_1 crossref_primary_10_1186_s12948_021_00149_6 crossref_primary_10_1172_JCI61303 crossref_primary_10_7759_cureus_25421 crossref_primary_10_1016_j_cpcardiol_2021_101088 crossref_primary_10_1016_j_clim_2009_01_006 crossref_primary_10_1016_j_jaad_2009_06_053 crossref_primary_10_3109_03009742_2015_1030448 crossref_primary_10_1038_nrrheum_2012_118 crossref_primary_10_1080_10739680802564787 crossref_primary_10_3390_biomedicines8070230 |
ContentType | Journal Article |
Copyright | Birkhäuser Verlag, Basel 2007 |
Copyright_xml | – notice: Birkhäuser Verlag, Basel 2007 |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7QL 7T5 7T7 7TM 7TO 7U9 7X7 7XB 88E 8AO 8FD 8FI 8FJ 8FK ABUWG AFKRA BENPR C1K CCPQU FR3 FYUFA GHDGH H94 K9. M0S M1P M7N P64 PQEST PQQKQ PQUKI PRINS 7X8 |
DOI | 10.1007/s00011-007-7024-3 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Immunology Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Technology Research Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Databases Environmental Sciences and Pollution Management ProQuest One Community College Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biotechnology and BioEngineering Abstracts ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Oncogenes and Growth Factors Abstracts Technology Research Database Nucleic Acids Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Pharma Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts Engineering Research Database ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | Oncogenes and Growth Factors Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Databases url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1420-908X |
EndPage | 420 |
ExternalDocumentID | 1386199911 10_1007_s00011_007_7024_3 18026698 |
Genre | Journal Article |
GroupedDBID | --- -4W -56 -5G -BR -EM -Y2 -~C .55 .86 .GJ .VR 06C 06D 0R~ 0VY 199 1N0 2.D 203 28- 29I 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 3O- 3SX 3V. 4.4 406 408 409 40D 40E 53G 5GY 5QI 5RE 5VS 67N 67Z 6NX 78A 7X7 88E 8AO 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAEOY AAHNG AAIAL AAJBT AAJKR AANXM AANZL AAQLM AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABJNI ABJOX ABKCH ABKTR ABMNI ABMQK ABNWP ABOCM ABPLI ABQBU ABSXP ABTEG ABTHY ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHXU ACIPQ ACKNC ACMDZ ACMLO ACOKC ACOMO ACPRK ACZOJ ADBBV ADHIR ADIMF ADINQ ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADYPR ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFEXP AFGCZ AFKRA AFLOW AFQWF AFRAH AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AOCGG ARMRJ AXYYD AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BPHCQ BVXVI CAG CCPQU CGR COF CS3 CSCUP CUY CVF DDRTE DL5 DNIVK DPUIP DU5 EBD EBLON EBS ECM EIF EIOEI EJD EN4 EPAXT ESBYG FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ IHE IJ- IKXTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH LAS LLZTM M1P M4Y MA- N2Q NB0 NDZJH NPM NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD P19 P2P PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R89 R9I RHV RNI ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S3A S3B SAP SBL SBY SCLPG SDH SDM SHX SISQX SJYHP SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SZN T13 T16 TEORI TSG TSK TSV TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WH7 WJK WK6 WK8 X7M Y6R YLTOR Z45 Z7U Z7W Z82 Z87 Z8O Z8Q Z8V Z91 ZGI ZMTXR ZOVNA ZXP ~EX ~KM AAYXX ADOAH CITATION 7QL 7T5 7T7 7TM 7TO 7U9 7XB 8FD 8FK C1K FR3 H94 K9. M7N P64 PQEST PQUKI PRINS 7X8 |
ID | FETCH-LOGICAL-c357t-f3b6ef43bc1b4be5a7c5c1a478ada0f3ae5bf293304b731dd0932c9d8673cec93 |
IEDL.DBID | BENPR |
ISSN | 1023-3830 |
IngestDate | Fri Oct 25 08:28:24 EDT 2024 Fri Oct 25 07:46:48 EDT 2024 Thu Oct 10 22:22:11 EDT 2024 Thu Sep 12 18:14:02 EDT 2024 Tue Oct 15 23:33:52 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 10 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c357t-f3b6ef43bc1b4be5a7c5c1a478ada0f3ae5bf293304b731dd0932c9d8673cec93 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 18026698 |
PQID | 216238920 |
PQPubID | 24296 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_68532128 proquest_miscellaneous_20502927 proquest_journals_216238920 crossref_primary_10_1007_s00011_007_7024_3 pubmed_primary_18026698 |
PublicationCentury | 2000 |
PublicationDate | 2007-Oct 2007-10-00 20071001 |
PublicationDateYYYYMMDD | 2007-10-01 |
PublicationDate_xml | – month: 10 year: 2007 text: 2007-Oct |
PublicationDecade | 2000 |
PublicationPlace | Switzerland |
PublicationPlace_xml | – name: Switzerland – name: New York |
PublicationTitle | Inflammation research |
PublicationTitleAlternate | Inflamm Res |
PublicationYear | 2007 |
Publisher | Springer Nature B.V |
Publisher_xml | – name: Springer Nature B.V |
SSID | ssj0008282 |
Score | 1.9100074 |
Snippet | Inflammation is associated with the invasion of leukocytes into affected tissues and with the up-regulation of platelet activation and adhesion. Assuming that... Objective: Inflammation is associated with the invasion of leukocytes into affected tissues and with the up-regulation of platelet activation and adhesion.... OBJECTIVEInflammation is associated with the invasion of leukocytes into affected tissues and with the up-regulation of platelet activation and adhesion.... |
SourceID | proquest crossref pubmed |
SourceType | Aggregation Database Index Database |
StartPage | 414 |
SubjectTerms | Animals Arthritis, Experimental - blood Arthritis, Experimental - drug therapy Cell Communication - drug effects Endothelial Cells - drug effects Endothelial Cells - physiology Female Leukocytes - drug effects Leukocytes - physiology Mice Mice, Inbred C57BL Platelet Aggregation Inhibitors - pharmacology Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors Tyrosine - analogs & derivatives Tyrosine - pharmacology |
Title | Selective inhibition of platelets by the GPIIb/IIIa receptor antagonist Tirofiban reduces leukocyte-endothelial cell interaction in murine antigen-induced arthritis |
URI | https://www.ncbi.nlm.nih.gov/pubmed/18026698 https://www.proquest.com/docview/216238920 https://search.proquest.com/docview/20502927 https://search.proquest.com/docview/68532128 |
Volume | 56 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3Nb9MwFLdYd-GC-KYMxjugHdCsOXYcJycEaGNBYqqgk3qL_BVWUZKytIf-P_yhPDtpKw7jZsmWE_k9v2__HiFvrcy1ksZRlSQBVDvxVHOvaIaSz3POstqFeMfXq-zyOv0yk7OhNqcbyiq3MjEKatfaECM_4wkq6rzg7P3yNw1No0JydeigcUAOOToKbEQOP55fTb7tRDG6E326kwuKrtgurckiimiMDjJFFeopKv5VTHdYm1HrXDwkDwZzET709H1E7vnmMTmZ9HjTm1OY7p9PdadwApM9EvXmCfnzPXa5QYEG8-ZmbmJ5FrQ1LBdoYiLFOjAbQBMQPk_K0pyVZakBRaBfoicOeOb6RxuQdWE6D629jW5w1iEzdLDw65-t3aw89Y0Lr7gWyMgQ0gAQEChu-_cSOIZfIZ7vw24B-JPOm7CBA2TZmwio9JRcX5xPP13SoS0DtUKqFa2FyXydCmMTkxovtbLSJjpVuXaa1UJ7aWoeAyVGicQ5hjaiLVyeKWG9LcQzMmraxr8gIL0xhRe1SGyR2gCPVzhpTZbULMu1Tcfk3ZYm1bJH36h2OMuRgFUYBgJWYkyOtlSrhovYVTu2GZM3u1m8QeE8dOPbNS5hkvGCq7tXZGjToIrPx-R5zwz7n8nRh82K_OV_v31E7seQcKwBfEVGq9u1f422zMockwM1U8cD3_4Ff6z3pw |
link.rule.ids | 315,783,787,12068,21400,27936,27937,31731,31732,33756,33757,43322,43817,74073,74630 |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3Nb9MwFLdgHOCC-KYM2DugHdCsJXEcJyeEEKOBbapEJ_UW-SusoiRlbQ_9f_hDec9JU3EYN0u2nMjv-X379xh7Z2WulTSOqzgmUO3Yc514xTOUfD5Joqx2FO-4uMzGV-nXmZz1tTmrvqxyJxODoHatpRj5aRKjos6LJPqw_M2paRQlV_sOGnfZPYLhogYGajb4WwTO1iU7E8HRERuSmlHAEA2xwUhxhVqKi3_V0i22ZtA5Z4_Yw95YhI8ddR-zO755wo4nHdr09gSm-8dTqxM4hskeh3r7lP35HnrcoDiDeXM9N6E4C9oalgs0MJFeKzBbQAMQvkzK0pyWZakBBaBfoh8OeOL6R0u4ujCdU2NvoxucdcgKK1j4zc_Wbtee-8bRG64FsjFQEgAIf-Kmey2BY_hF0XxPuxHsJ583tIEDZNjrAKf0jF2dfZ5-GvO-KQO3Qqo1r4XJfJ0KY2OTGi-1stLGOlW5djqqhfbS1EkIkxglYucitBBt4fJMCettIZ6zg6Zt_EsG0htTeFGL2BapJXC8wklrsriOslzbdMTe72hSLTvsjWpAWQ4ErGhIBKzEiB3uqFb113BVDUwzYkfDLN4fOg_d-HaDSyIZJUWibl-RoUWDCj4fsRcdM-x_JkcPNivyV__99hG7P55enFfn5eW3Q_YgBIdDNeBrdrC-2fg3aNWszdvAu38BVUH4Sw |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Jj9MwFLagIyEuiH3KAOMDmgMaq04c28kJsUyZsFQRdKS5Rd7CVJSkTNpD_w8_lGcnTcVhuFmy5UR-z2_39xB6ZXiqJNeWyCjyoNqRIyp2kgiQfC6Oqaisj3d8nYnzi-TTJb_sIYXavqxyJxODoLaN8THySRyBok6zmE6qviqi-DB9s_pNfAMpn2jtu2ncRgcyEYyO0MG7s1nxbRDL4Fp0qc-YEXDLhhQnDYiiIVJIJZGgswj7V0ndYHkGDTS9j-71piN-29H6Abrl6ofopOiwp7eneL5_StWe4hNc7FGpt4_Qn--h4w0IN7yorxY6lGrhpsKrJZibQL0W6y0GcxB_LPJcT_I8VxjEoVuBV47h_NWPxqPs4vnCt_nWqoZZC4zR4qXb_GzMdu2Iq61_0bUEpsY-JYA9GsV193YCxviXj-07v5sHASWL2m9gMbDvVQBXeowupmfz9-ekb9FADONyTSqmhasSpk2kE-24koabSCUyVVbRiinHdRWHoImWLLKWgr1oMpsKyYwzGXuCRnVTu0OEudM6c6xikckS46HyMsuNFlFFRapMMkavdzQpVx0SRzlgLgcCln7oCViyMTraUa3sL2VbDiw0RsfDLNwmfx6qds0GllBO4yyWN68QYN-Auk_H6GnHDPufScGfFVn67L_fPkZ3gHHLL_ns8xG6GyLFoTTwORqtrzfuBZg4a_2yZ96_BR_96A |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Selective+inhibition+of+platelets+by+the+GPIIb%2FIIIa+receptor+antagonist+Tirofiban+reduces+leukocyte-endothelial+cell+interaction+in+murine+antigen-induced+arthritis&rft.jtitle=Inflammation+research&rft.au=Schmitt-Sody%2C+M&rft.au=Mete%2C+P&rft.au=Gottschalk%2C+O&rft.au=Zysk%2C+S&rft.date=2007-10-01&rft.issn=1023-3830&rft.volume=56&rft.issue=10&rft.spage=414&rft.epage=420&rft_id=info:doi/10.1007%2Fs00011-007-7024-3&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1023-3830&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1023-3830&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1023-3830&client=summon |